Nadia Benabdallah, PhD

Washington University in St. Louis (WU)

My clinical and research interests are centered on radiopharmaceutical therapy (RPT), spanning both preclinical and clinical dosimetry. I am focused on developing robust dosimetric frameworks, especially in alpha thereapy, with the goal of personalizing treatment planning and improving therapeutic outcomes. A key area of my research involves correlating absorbed dose estimates with biological response — investigating how dosimetric parameters relate to observed biomarkers across treatment cycles. I am particularly interested in identifying laboratory biomarkers that serve as early predictors of organ toxicity, enabling more proactive patient management during RPT. Complementing this work, I am engaged in optimizing SPECT/CT imaging protocols to improve quantitative accuracy in activity quantification, which is foundational to reliable dosimetry. Together, these efforts aim to bridge the gap between imaging physics and clinical decision-making, advancing the safe and effective delivery of targeted radionuclide therapies.